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Introduction
The Translational Bioinformatics Conference (TBC) has
been one of the most successful multi-disciplinary con-
ferences in the rapidly emerging fields of bioinformatics
and clinical genomics for their bidirectional translations.
The Fourth Annual TBC 2014 jointly held with the 8th
International Conference on Systems Biology meeting
for four days at the Huiquan Dynasty Hotel, Qingdao,
China, improved our understanding of novel diagnostics
and therapeutics in the era of biomedical big data.
While TBC is organized as an international forum for
translational bioinformatics, the first three annual meet-
ings of TBC have been held in Korea since 2011. We
appreciate the Chinese Academy of Sciences for hosting
TBC 2014 and making TBC a truly international one.
Japanese Association of Medical Informatics (JAMI) has
unanimously approved to host TBC 2015 in Tokyo in
early November, 2015. TBC 2016 will either be held in
India or United States. It is a great pleasure to see the
real growth of TBC.
NIH Director Francis S. Collins said, “Data creation in
today’s research is exponentially more rapid than any-
thing we anticipated even a decade ago.” The ability to
connecting the dots in the wealth biomedical big data
will bring us the ‘big picture’ in a mass of genes, drugs,
diseases, and diagnostic, therapeutic and prognostic mar-
kers. Steve Jobs said, “You can’t connect the dots looking
forward; you can only connect them looking backwards.
So you have to trust that the dots will somehow connect
in your future.” Personalized medicine attempts to deter-
mine individual solutions based on the genomic and clin-
ical profiles of each individual, providing opportunity to
incorporate individual molecular data into patient care.
While a plethora of genomic signatures have successfully
demonstrated their predictive power, they are merely sta-
tistically-significant differences between dichotomized
phenotypes that are in fact severely heterogeneous.
Despite many translational barriers, connecting the mole-
cular world to the clinical world and vice versa will
undoubtedly benefit human health in the near future.
Novel therapeutics and diagnostics markers for
personalizing healthcare
Connecting experimental and/or observational data with
factual bio-databases and biomedical literatures is an
essential step in the course of translational bioinformatics
analysis. Grover et al. (Deakin U., Australia) applied Gen-
trepid [1], a candidate gene prediction method empow-
ered by five bioinformatics modules, to reanalyze
Welcome Trust Case-Control Consortium GWAS data
for coronary artery disease and successfully replicated
55% of the candidate genes identified by CARDIoGRAM-
plusC4D consortium meta-analysis [2]. By integrating the
predicted candidate genes with the Therapeutic Target
Database, PharmGKB, and DrugBank, they were able to
identify highly-validated novel therapeutics feasible for
repositioning as well as therapeutic target genes. Con-
necting drug-gene-disease associations is further boosted
by adding protein complex information by Yu et al.
(Xidan U., China) [3] who obtained indirect weighted
bipartite relationships between drugs and diseases from
the tripartite drug-gene-disease network. They performed
two case studies for mental disorders and hypertension
and successfully validated their network with compara-
tive toxicogenomics database (http://ctdbase.org). Zhu
et al. (Wuhan U.) integrated gene-expression prognostic
markers for breast-cancer survival from Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) with drug
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sensitivity data extracted from the Developmental Thera-
peutic Program database (http://dtp.nci.nih.gov/). They
were able to suggest a few repositioned drugs for breast
cancer [4].
Despite of comprehensive databases and bioinformatics
tools for analyzing genetic variants, genome interpreta-
tion at the personal level still remains a challenging goal.
Na et al. (Seoul National U., Korea) proposed a computa-
tional scheme to connect individual personal genomes to
disease predispositions for the purpose of personal gen-
ome interpretation [5]. Given a personal genome, they
computed functional impacts of all potentially damaging
missense variants by using the Sorting Intolerant From
Tolerant (SIFT) algorithm [6]. Disease-gene links were
obtained from the Online Mendelian Inheritance in Man
(OMIM) by simultaneously considering the hierarchical
structure of MeSH (Medical Subject Headings) terms.
Similarity structure analysis with all-pairwise computa-
tion of mutual information between the SIFT-score vec-
tors of variants of the personal genomes and the disease-
gene association-score vectors revealed the connections
between personal genomes and diseases.
Connecting the dots can be corrected in a relevant
manner looking backward. While cancer cell lines have
been extensively used for cancer research, measures for
the similarity between cell lines and tumors are not fully
established. Chen et al. connected 200 hepatocellular
carcinoma (HCC) tumor samples from the The Cancer
Genome Atlas and over 1000 cancer cell lines by using
gene expression data [7]. While the most commonly
used HCC cell lines resembled primary HCC tumors,
nearly half of the cell lines did not. Selection of cancer
cell lines may be benefited by the relevance measures of
specific genes under investigation between the dots.
Translational epigenomics
Connecting a variety of epigenomic mechanisms includ-
ing histone modifications, post-transcriptional modifica-
tions (PTMs), and RNA editings to genes, drugs, and
diseases, for investigating epigenomic regulations needs
much more work to be done by translational bioinfor-
matics researchers. Yang et al. (Chicago U., U.S.A.) pro-
posed a computational scheme to integrate tissue-specific
histone modifications and genome-wide transcriptional
regulation [8]. While therapy-related, secondary acute
myeloid leukemia (t-AML) has been suggested to be
related to the suppression of a histone methyltransferase,
EZH2, the critical target genes of EZH2 and their regula-
tory roles are largely unknown. Yang et al. developed the
‘seq2gene’ algorithm to explore target genes of immune-
precipitation sequencing (ChIP-seq) enriched regions
and then extracted regulatory ‘biomodules’ enriched with
genes with similar expression profile and genomic or
functional characteristics by combining the seq2gene
algorithm with Phenotype-Genotype-Network (PGnet)
algorithm [9]. This preliminary analysis suggested
SEMA3A (Semaphoring 3A) as a novel oncogenic candi-
date that is regulated by EZH2 silencing and warranted
further study.
Altered PTM sites may be resulted by non-synon-
ymous SNPs (nsSNPs) in the coding regions that are
disease-associated. Kim et al (KAIST, Korea) created
an open-access PTM-SNP database for comprehensive
collection of human SNPs that affect PTM sites
together with human disease associations extracted
from GWAS catalogs [10]. They found that PTM-SNPs
are highly enriched with human disease-associated
nsSNPs. Post-transcriptional sequence modification of
transcripts through RNA editing is also an important
mechanism for regulating protein function and is asso-
ciated with many human diseases. Lee et al. (Seoul
National U., Korea) created RCARE (RNA-Seq Com-
parison and Annotation for RNA Editing) for search-
ing, annotating, and visualizing RNA-DNA difference
(RDD) sites [11]. RCARE as an open-access toolkit
tries to manage problematic false positives, determine
the location of condition-specific RDD sites, and eluci-
date their functional roles with evidence levels, sum-
mary plots and executive summary.
Translating disease networks and network
biomarkers
Despite the plethora of high-throughput data and the
recent advances in next-generation sequencing technolo-
gies, correctly connecting the multi-level biomedical net-
works remains challenging. Network-based analysis of
public databases and numerous biomedical knowledge
resources are invaluable for a high profile translational
bioinformatics research. Carson et al (U. of Illinois at
Chicago) investigated human protein interaction network
using the Disease Ontology in an attempt to identify dis-
ease-associated vs. non-disease-associated proteins [12].
Using a bootstrapping method, they created and trained
an alternating decision tree classifier to extract conserved
characteristics shared by disease-associated proteins with
79% area under the receiver operating curve. A variety of
network properties and first- and second-order neigh-
bours in the protein interaction network could improve
the overall performance. To overcome the classical gene
biomarker detection methods based on differentially
expressed genes (DEGs) in studies with small number of
samples, resulting too many false positives and low statis-
tical power, Hur et al. (Seoul National U., Korea) pro-
posed a multi-step filtering method to predict gene
biomarkers from RNA-Seq data of case-control mouse-
knockout studies [13]. They devised four-step filtering
methods gradually combining DEG fold change, gene
regulatory network membership, biological pathway
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membership, and single nucleotide variant frequency fil-
ters, to carefully reduce candidate gene biomarkers.
Rather than detecting individual molecular biomarkers,
Xin et al. (Chinese Academy of Sciences, China) devel-
oped a method to detect biomarkers at a network level
based on protein-protein interaction affinity (PPIA) net-
work modelling using linear programming [14].
Methods for high performance translation
Better bioinformatics tools and methods are required for
a successful translational research. In this issue, advanced
solutions for well-known bioinformatics problems were
introduced. Sandhan et al. (Seoul National U., Korea)
proposed a protein function prediction method [15]. To
overcome classical prediction methods that rely mainly
on strong global features and sequence homologies, they
constructed protein-protein similarity network that con-
siders both global and local features, by capturing
weakly-interacting pairs and by using the hierarchical
voting algorithm via the graph pyramid. Wang et al. (Xia-
men U., China) proposed SeedsGraph, a new de novo
sequence assembly algorithm for whole-genome shotgun
assembly in a cloud computing framework [16]. The
MapReduce framework is used for the first sequence-
read overlap step for short reads to reduce computational
cost. The overlap graphs are then clustered into groups
and compressed into chains of seeds that are used to
construct a seeds graph by seeds overlapping. PDEGEM
(Positional Dependent Energy Guided Expression Model)
is proposed as a novel algorithm for estimating transcript
abundances for RNA-Seq data by Xia et al. (Peking U.,
China) [17] based on Positional Dependent Nearest
Neighbourhood model. Hayashida et al. (Kyoto U., Japan)
introduced three parallelized algorithms, BfsEnumP1-3,
by modifying their previous algorithm, BfsSimEnum, for
enumerating tree-like chemical compounds without mul-
tiple bonds [18]. Enumerating chemical compound is
essential in designing and finding new drugs and deter-
mining chemical structures from mass spectrometry data.
By dividing a set of vertices into several subsets and
assigning them to microprocessors, BfsEnumP1-3 greatly
reduced execution time with high parallelization
efficiency.
This meeting, TBC 2014, provided an international
forum for translational bioinformatics and clinical geno-
mics researchers to bring together and substantially
improve our understanding of molecular and pathophy-
siologic foundations of human diseases and health.
I congratulate the speakers and authors to this confer-
ence who are shaping the future of personalized diag-
nostic, prognostics and therapeutics. Today, many
health topics for personalized and precision medicine
are increasingly within the scope of translational bioin-
formatics. It would be fascinating for our generation to
see the transformation of traditional trial-and-error
medicine into informatically-empowered personalized-
and-precision medicine.
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